Fenway Health has launched an exciting new study focusing on transgender and non-binary people’s health called The LEGACY Project and we need your help to make it a success!
The goal of this multi-site study — which is being led, designed, and run by transgender and non-binary people — is to examine how medical gender affirmation impacts quality of life, mental health outcomes, and HIV-related outcomes among 4,500 transgender and non-binary adult patients from Fenway Health and Callen-Lorde Community Health Center in New York City.
The LEGACY Project will be integrated with medical care at Fenway and Callen-Lorde. De-identified data for this study will be collected from patients’ electronic medical records. Additionally, patients will be asked to complete three surveys over the course of one year to help supplement this information. Patients will have to consent to take the additional surveys, and have the option to take the surveys on site or at home. We will be enrolling patients from February 2019 until January 2020.
Why “LEGACY,” you ask? The hard-fought rights of transgender and non-binary people have been under attack in recent years. The trending hashtag #WontBeErased was created in support of transgender and non-binary folks. We chose “LEGACY” to echo this sentiment — that the legacy and health of transgender, non-binary, and gender diverse people will not be erased or silenced.
If you have any questions about the study or would like to enroll, please contact LEGACYProject@fenwayhealth.org.
We hope you’ll join us in building the LEGACY of transgender and non-binary health!
Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (AD-2017C1-6569). The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.
Want to receive email updates about what’s happening at Fenway Health? Sign up here.